Stereotactic radiosurgery for arteriovenous malformations, Part 6: Multistaged volumetric management of large arteriovenous malformations: Clinical article

Hideyuki Kano, Douglas Kondziolka, John C. Flickinger, Kyung-Jae Park, Phillip V. Parry, Huai Che Yang, Sait Sirin, Ajay Niranjan, Josef Novotny, L. Dade Lunsford

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Object. The object of this study was to define the long-term outcomes and risks of arteriovenous malformation (AVM) management using 2 or more stages of stereotactic radiosurgery (SRS) for symptomatic large-volume lesions unsuitable for surgery. Methods. In 1992, the authors prospectively began to stage the treatment of anatomical components to deliver higher single doses to AVMs with a volume of more than 10 cm 3. Forty-seven patients with such AVMs underwent volume-staged SRS. In this series, 18 patients (38%) had a prior hemorrhage and 21 patients (45%) underwent prior embolization. The median interval between the first-stage SRS and the second-stage SRS was 4.9 months (range 2.8-13.8 months). The median target volume was 11.5 cm 3 (range 4.0-26 cm 3) in the first-stage SRS and 9.5 cm 3 in the second-stage SRS. The median margin dose was 16 Gy (range 13-18 Gy) for both stages. Results. In 17 patients, AVM obliteration was confirmed after 2-4 SRS procedures at a median follow-up of 87 months (range 0.4-209 months). Five patients had near-total obliteration (volume reduction > 75% but residual AVM). The actuarial rates of total obliteration after 2-stage SRS were 7%, 20%, 28%, and 36% at 3, 4, 5, and 10 years, respectively. The 5-year total obliteration rate after the initial staged volumetric SRS with a margin dose of 17 Gy or more was 62% (p = 0.001). Sixteen patients underwent additional SRS at a median interval of 61 months (range 33-113 months) after the initial 2-stage SRS. The overall rates of total obliteration after staged and repeat SRS were 18%, 45%, and 56% at 5, 7, and 10 years, respectively. Ten patients sustained hemorrhage after staged SRS, and 5 of these patients died. Three of 16 patients who underwent repeat SRS sustained hemorrhage after the procedure and died. Based on Kaplan-Meier analysis (excluding the second hemorrhage in the patient who had 2 hemorrhages), the cumulative rates of AVM hemorrhage after SRS were 4.3%, 8.6%, 13.5%, and 36.0% at 1, 2, 5, and 10 years, respectively. This corresponded to annual hemorrhage risks of 4.3%, 2.3%, and 5.6% for Years 0-1, 1-5, and 5-10 after SRS. Multiple hemorrhages before SRS correlated with a significantly higher risk of hemorrhage after SRS. Symptomatic adverse radiation effects were detected in 13% of patients, but no patient died as a result of an adverse radiation effect. Delayed cyst formation did not occur in any patient after SRS. Conclusions. Prospective volume-staged SRS for large AVMs unsuitable for surgery has potential benefit but often requires more than 2 procedures to complete the obliteration process. To have a reasonable chance of benefit, the minimum margin dose should be 17 Gy or greater, depending on the AVM location. In the future, prospective volumestaged SRS followed by embolization (to reduce flow, obliterate fistulas, and occlude associated aneurysms) may improve obliteration results and further reduce the risk of hemorrhage after SRS.

Original languageEnglish
Pages (from-to)54-65
Number of pages12
JournalJournal of Neurosurgery
Volume116
Issue number1
DOIs
Publication statusPublished - 2012 Jan 1
Externally publishedYes

Fingerprint

Radiosurgery
Arteriovenous Malformations
Hemorrhage
Radiation Effects

Keywords

  • Arteriovenous malformation
  • Complications
  • Gamma Knife surgery
  • Large aneurysm
  • Staged radiosurgery
  • Stereotactic radiosurgery

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Stereotactic radiosurgery for arteriovenous malformations, Part 6 : Multistaged volumetric management of large arteriovenous malformations: Clinical article. / Kano, Hideyuki; Kondziolka, Douglas; Flickinger, John C.; Park, Kyung-Jae; Parry, Phillip V.; Yang, Huai Che; Sirin, Sait; Niranjan, Ajay; Novotny, Josef; Lunsford, L. Dade.

In: Journal of Neurosurgery, Vol. 116, No. 1, 01.01.2012, p. 54-65.

Research output: Contribution to journalArticle

Kano, Hideyuki ; Kondziolka, Douglas ; Flickinger, John C. ; Park, Kyung-Jae ; Parry, Phillip V. ; Yang, Huai Che ; Sirin, Sait ; Niranjan, Ajay ; Novotny, Josef ; Lunsford, L. Dade. / Stereotactic radiosurgery for arteriovenous malformations, Part 6 : Multistaged volumetric management of large arteriovenous malformations: Clinical article. In: Journal of Neurosurgery. 2012 ; Vol. 116, No. 1. pp. 54-65.
@article{902d13562de24c6d89b97350337d71af,
title = "Stereotactic radiosurgery for arteriovenous malformations, Part 6: Multistaged volumetric management of large arteriovenous malformations: Clinical article",
abstract = "Object. The object of this study was to define the long-term outcomes and risks of arteriovenous malformation (AVM) management using 2 or more stages of stereotactic radiosurgery (SRS) for symptomatic large-volume lesions unsuitable for surgery. Methods. In 1992, the authors prospectively began to stage the treatment of anatomical components to deliver higher single doses to AVMs with a volume of more than 10 cm 3. Forty-seven patients with such AVMs underwent volume-staged SRS. In this series, 18 patients (38{\%}) had a prior hemorrhage and 21 patients (45{\%}) underwent prior embolization. The median interval between the first-stage SRS and the second-stage SRS was 4.9 months (range 2.8-13.8 months). The median target volume was 11.5 cm 3 (range 4.0-26 cm 3) in the first-stage SRS and 9.5 cm 3 in the second-stage SRS. The median margin dose was 16 Gy (range 13-18 Gy) for both stages. Results. In 17 patients, AVM obliteration was confirmed after 2-4 SRS procedures at a median follow-up of 87 months (range 0.4-209 months). Five patients had near-total obliteration (volume reduction > 75{\%} but residual AVM). The actuarial rates of total obliteration after 2-stage SRS were 7{\%}, 20{\%}, 28{\%}, and 36{\%} at 3, 4, 5, and 10 years, respectively. The 5-year total obliteration rate after the initial staged volumetric SRS with a margin dose of 17 Gy or more was 62{\%} (p = 0.001). Sixteen patients underwent additional SRS at a median interval of 61 months (range 33-113 months) after the initial 2-stage SRS. The overall rates of total obliteration after staged and repeat SRS were 18{\%}, 45{\%}, and 56{\%} at 5, 7, and 10 years, respectively. Ten patients sustained hemorrhage after staged SRS, and 5 of these patients died. Three of 16 patients who underwent repeat SRS sustained hemorrhage after the procedure and died. Based on Kaplan-Meier analysis (excluding the second hemorrhage in the patient who had 2 hemorrhages), the cumulative rates of AVM hemorrhage after SRS were 4.3{\%}, 8.6{\%}, 13.5{\%}, and 36.0{\%} at 1, 2, 5, and 10 years, respectively. This corresponded to annual hemorrhage risks of 4.3{\%}, 2.3{\%}, and 5.6{\%} for Years 0-1, 1-5, and 5-10 after SRS. Multiple hemorrhages before SRS correlated with a significantly higher risk of hemorrhage after SRS. Symptomatic adverse radiation effects were detected in 13{\%} of patients, but no patient died as a result of an adverse radiation effect. Delayed cyst formation did not occur in any patient after SRS. Conclusions. Prospective volume-staged SRS for large AVMs unsuitable for surgery has potential benefit but often requires more than 2 procedures to complete the obliteration process. To have a reasonable chance of benefit, the minimum margin dose should be 17 Gy or greater, depending on the AVM location. In the future, prospective volumestaged SRS followed by embolization (to reduce flow, obliterate fistulas, and occlude associated aneurysms) may improve obliteration results and further reduce the risk of hemorrhage after SRS.",
keywords = "Arteriovenous malformation, Complications, Gamma Knife surgery, Large aneurysm, Staged radiosurgery, Stereotactic radiosurgery",
author = "Hideyuki Kano and Douglas Kondziolka and Flickinger, {John C.} and Kyung-Jae Park and Parry, {Phillip V.} and Yang, {Huai Che} and Sait Sirin and Ajay Niranjan and Josef Novotny and Lunsford, {L. Dade}",
year = "2012",
month = "1",
day = "1",
doi = "10.3171/2011.9.JNS11177",
language = "English",
volume = "116",
pages = "54--65",
journal = "Journal of Neurosurgery",
issn = "0022-3085",
publisher = "American Association of Neurological Surgeons",
number = "1",

}

TY - JOUR

T1 - Stereotactic radiosurgery for arteriovenous malformations, Part 6

T2 - Multistaged volumetric management of large arteriovenous malformations: Clinical article

AU - Kano, Hideyuki

AU - Kondziolka, Douglas

AU - Flickinger, John C.

AU - Park, Kyung-Jae

AU - Parry, Phillip V.

AU - Yang, Huai Che

AU - Sirin, Sait

AU - Niranjan, Ajay

AU - Novotny, Josef

AU - Lunsford, L. Dade

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Object. The object of this study was to define the long-term outcomes and risks of arteriovenous malformation (AVM) management using 2 or more stages of stereotactic radiosurgery (SRS) for symptomatic large-volume lesions unsuitable for surgery. Methods. In 1992, the authors prospectively began to stage the treatment of anatomical components to deliver higher single doses to AVMs with a volume of more than 10 cm 3. Forty-seven patients with such AVMs underwent volume-staged SRS. In this series, 18 patients (38%) had a prior hemorrhage and 21 patients (45%) underwent prior embolization. The median interval between the first-stage SRS and the second-stage SRS was 4.9 months (range 2.8-13.8 months). The median target volume was 11.5 cm 3 (range 4.0-26 cm 3) in the first-stage SRS and 9.5 cm 3 in the second-stage SRS. The median margin dose was 16 Gy (range 13-18 Gy) for both stages. Results. In 17 patients, AVM obliteration was confirmed after 2-4 SRS procedures at a median follow-up of 87 months (range 0.4-209 months). Five patients had near-total obliteration (volume reduction > 75% but residual AVM). The actuarial rates of total obliteration after 2-stage SRS were 7%, 20%, 28%, and 36% at 3, 4, 5, and 10 years, respectively. The 5-year total obliteration rate after the initial staged volumetric SRS with a margin dose of 17 Gy or more was 62% (p = 0.001). Sixteen patients underwent additional SRS at a median interval of 61 months (range 33-113 months) after the initial 2-stage SRS. The overall rates of total obliteration after staged and repeat SRS were 18%, 45%, and 56% at 5, 7, and 10 years, respectively. Ten patients sustained hemorrhage after staged SRS, and 5 of these patients died. Three of 16 patients who underwent repeat SRS sustained hemorrhage after the procedure and died. Based on Kaplan-Meier analysis (excluding the second hemorrhage in the patient who had 2 hemorrhages), the cumulative rates of AVM hemorrhage after SRS were 4.3%, 8.6%, 13.5%, and 36.0% at 1, 2, 5, and 10 years, respectively. This corresponded to annual hemorrhage risks of 4.3%, 2.3%, and 5.6% for Years 0-1, 1-5, and 5-10 after SRS. Multiple hemorrhages before SRS correlated with a significantly higher risk of hemorrhage after SRS. Symptomatic adverse radiation effects were detected in 13% of patients, but no patient died as a result of an adverse radiation effect. Delayed cyst formation did not occur in any patient after SRS. Conclusions. Prospective volume-staged SRS for large AVMs unsuitable for surgery has potential benefit but often requires more than 2 procedures to complete the obliteration process. To have a reasonable chance of benefit, the minimum margin dose should be 17 Gy or greater, depending on the AVM location. In the future, prospective volumestaged SRS followed by embolization (to reduce flow, obliterate fistulas, and occlude associated aneurysms) may improve obliteration results and further reduce the risk of hemorrhage after SRS.

AB - Object. The object of this study was to define the long-term outcomes and risks of arteriovenous malformation (AVM) management using 2 or more stages of stereotactic radiosurgery (SRS) for symptomatic large-volume lesions unsuitable for surgery. Methods. In 1992, the authors prospectively began to stage the treatment of anatomical components to deliver higher single doses to AVMs with a volume of more than 10 cm 3. Forty-seven patients with such AVMs underwent volume-staged SRS. In this series, 18 patients (38%) had a prior hemorrhage and 21 patients (45%) underwent prior embolization. The median interval between the first-stage SRS and the second-stage SRS was 4.9 months (range 2.8-13.8 months). The median target volume was 11.5 cm 3 (range 4.0-26 cm 3) in the first-stage SRS and 9.5 cm 3 in the second-stage SRS. The median margin dose was 16 Gy (range 13-18 Gy) for both stages. Results. In 17 patients, AVM obliteration was confirmed after 2-4 SRS procedures at a median follow-up of 87 months (range 0.4-209 months). Five patients had near-total obliteration (volume reduction > 75% but residual AVM). The actuarial rates of total obliteration after 2-stage SRS were 7%, 20%, 28%, and 36% at 3, 4, 5, and 10 years, respectively. The 5-year total obliteration rate after the initial staged volumetric SRS with a margin dose of 17 Gy or more was 62% (p = 0.001). Sixteen patients underwent additional SRS at a median interval of 61 months (range 33-113 months) after the initial 2-stage SRS. The overall rates of total obliteration after staged and repeat SRS were 18%, 45%, and 56% at 5, 7, and 10 years, respectively. Ten patients sustained hemorrhage after staged SRS, and 5 of these patients died. Three of 16 patients who underwent repeat SRS sustained hemorrhage after the procedure and died. Based on Kaplan-Meier analysis (excluding the second hemorrhage in the patient who had 2 hemorrhages), the cumulative rates of AVM hemorrhage after SRS were 4.3%, 8.6%, 13.5%, and 36.0% at 1, 2, 5, and 10 years, respectively. This corresponded to annual hemorrhage risks of 4.3%, 2.3%, and 5.6% for Years 0-1, 1-5, and 5-10 after SRS. Multiple hemorrhages before SRS correlated with a significantly higher risk of hemorrhage after SRS. Symptomatic adverse radiation effects were detected in 13% of patients, but no patient died as a result of an adverse radiation effect. Delayed cyst formation did not occur in any patient after SRS. Conclusions. Prospective volume-staged SRS for large AVMs unsuitable for surgery has potential benefit but often requires more than 2 procedures to complete the obliteration process. To have a reasonable chance of benefit, the minimum margin dose should be 17 Gy or greater, depending on the AVM location. In the future, prospective volumestaged SRS followed by embolization (to reduce flow, obliterate fistulas, and occlude associated aneurysms) may improve obliteration results and further reduce the risk of hemorrhage after SRS.

KW - Arteriovenous malformation

KW - Complications

KW - Gamma Knife surgery

KW - Large aneurysm

KW - Staged radiosurgery

KW - Stereotactic radiosurgery

UR - http://www.scopus.com/inward/record.url?scp=84855398196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855398196&partnerID=8YFLogxK

U2 - 10.3171/2011.9.JNS11177

DO - 10.3171/2011.9.JNS11177

M3 - Article

C2 - 22077447

AN - SCOPUS:84855398196

VL - 116

SP - 54

EP - 65

JO - Journal of Neurosurgery

JF - Journal of Neurosurgery

SN - 0022-3085

IS - 1

ER -